We explored the influence of modifications of uridine 5'-methylenephosphonate on biological activity at the human P2Y 2 receptor. Key steps in the synthesis of a series of 5-substituted uridine 5'-methylenephosphonates were the reaction of a suitably protected uridine 5'-aldehyde with [(diethoxyphosphinyl)methylidene]triphenylphosphorane, C-5 bromination and a Suzuki-Miyaura coupling. These analogues behaved as selective agonists at the P2Y 2 receptor, with three analogues exhibiting potencies in the submicromolar range. Although maximal activities observed with the phosphonate analogues were much less than observed with UTP, high concentrations of the phosphonates had no effect on the stimulatory effect of UTP. These results suggest that these phosphonates bind to an allosteric site of the P2Y 2 receptor. 
Introduction
Extracellular purine and pyrimidine nucleosides and nucleotides act as messengers via specific receptors on the plasma membrane. These receptors exist in two families: P1 receptors (also termed adenosine receptors) activated by adenosine and P2 receptors activated by adenosine 5'-tri-or diphosphate (ATP or ADP) and/or uridine 5'-tri-or diphosphate (UTP or UDP). P2 receptors are further divided as P2X and P2Y receptors, which are ligand-gated ion channels and G protein-coupled receptors (GPCRs), respectively.
1,2,3,4 At least eight different subtypes of P2Y receptors are known, i.e. P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 and P2Y 14 . The missing numbers belong to non-mammalian receptors, which may be orthologs of mammalian subtypes, or receptors that do not appear to be bona-fide P2Y receptor family members. 5 of cystic fibrosis, cancer and dry eye syndrome, 8, 9 while P2Y 2 antagonists might have antiinflammatory 10 and neuroprotective effects.
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The major limitations associated with known agonists for the P2Y 2 receptor are (i) the lack of selectivity vs. closely related P2Y receptor subtypes and (ii) their fast degradation by nucleotide-hydrolyzing ecto-enzymes, which results in a relative short duration of action. 5 In that context, we recently explored to what extent replacement of the α-phosphate group of UTP by an isosteric phosphonate affected P2Y 2 receptor activity. 9 Since the carbonphosphorus bond cannot be hydrolyzed, this analogue was expected to exhibit prolonged metabolic stability. While we initially focused on a diphosphophosphonate mimic of UTP (2), it was fortuitously discovered that its synthetic precursor 3 was also capable of activating the In this study, we explore the influence of further modifications of the 5'-methylenephosphonate 3 on activity at the P2Y 2 receptor. A patent application from AstraZeneca indicated that incorporation of a large semiplanar, hydrophobic aromatic ring at position 5 of thiouridine triphosphate may be accommodated by the P2Y 2 receptor but tends to preclude the conformational change required for receptor activation. 12 Therefore, we introduced several smaller (hetero)aromatic substituents at the 5-position of analogue 3 to 2',2-O-anhydro analogue 9 was formed using thionyl chloride in CH 3 CN followed by the addition of NaOAc. 20 Introduction of an amino group at the 2' position was accomplished via opening of the anhydro-derivative 9 with NaN 3 in DMF. Interestingly, these conditions caused concomitant incomplete hydrolysis of the phosphonate ester to afford 10 as reported previously by Holy. 21 Staudinger reduction of the azide followed by deprotection of mono ethylphosphonate 11 resulted in the desired 2'-amino-2'-deoxyuridine-5'-phosphonate analogue 12. Similarly, treatment of 9 with a 2 N HCl in diethyl ether solution followed by the hydrolysis of the phosphonate diester resulted in 2'-chloro-2'-deoxy analogue 14. The synthesis of 4'-O-CH 2 phosphonate analogue 22 started from 2',3'-dideoxy-3',4'-didehydro-β-D-erythrofuranosyl)uracil 18 (Scheme 4). 25 Treatment of this glycal with phenylselenyl chloride at -70 °C followed by the addition of silver perchlorate in the presence of diethyl (hydroxymethyl)phosphonate afforded phosphonate 19 in 35% overall yield.
Assignment of the stereoarrangement in 19 was based on mechanistic considerations. 
Pharmacological Evaluation
Activities of analogues at the P2Y 2 receptor were determined measuring PLC-dependent phosphoinositide hydrolysis in 1321N1 human astrocytoma cells stably expressing the human P2Y 2 receptor (P2Y 2 -1321N1 cells). 27, 28 As previously shown for UTP and UDP 27 , none of the phosphonate analogues reproducibly promoted inositol phosphate accumulation in wildtype 1321N1 cells ( Fig. 2A) . The concentration of all phosphonate analogues was 100 M, of carbachol was 100 M, of UTP was 100 nM, and UDP was 1µM. In contrast, quantification of inositol phosphate accumulation in P2Y 2 receptor-expressing 1321N1 cells revealed that the newly synthesized 5'-methylenephosphonate analogues are P2Y 2 receptor agonists (Fig 2B) , although none of the analogues produced maximal effects at 100 M concentration as great as UTP. Given the novel activity observed with these phosphonate analogues at the P2Y 2 receptor, we also determined whether they interacted with the UTP-activated P2Y 4 receptor or the UDP-activated P2Y 6 receptor. Little or no reproducible stimulation was observed over basal activity for any of these analogues in 1321N1 human astrocytoma cells stably expressing the human P2Y 4 (Fig. 2C ) or human P2Y 6 (Fig. 2D) receptors.
Full concentration effect curves were generated in P2Y 2 -1321N1 cells with each of the analogues to more clearly assess their maximal effects relative to UTP and to establish their relative potencies as P2Y 2 receptor agonists. To enhance clarity of comparison of the relative activities of these analogues, the data are arbitrarily presented in four separate panels (Fig. 3 ). The 5-modified uridine 5'-phosphonate analogues activated the P2Y 2 receptor with a range of apparent potencies, and the maximal effect observed with each of these molecules was only 40-55% of that observed with UTP ( Fig. 3 and Table 1 ). The most potent agonists were the 5-(4-fluorophenyl) (7c), thien-2-yl (7g), and 5-(2-furanyl) (7f) analogues, which exhibited potencies in the submicromolar range (Table 1) .
Compound EC 50 , µM Max response 1 0.02 ± 0.003 100 3 5.1 ± 0.9 32 ± 9 7a 1.5 ± 0.5 53 ± 7 The activities of two of the most potent new compounds 7c and 7f were directly compared in the same experiments to the 5-unsubstituted parent compound 3 (Fig. 4) . Both analogues produced maximal effects at the P2Y 2 receptor that were similar to that of 3, but were approximately 10-fold more potent than this previously studied analogue. The idea that these modified uridine 5'-phosphonate analogues are orthosteric ligands that exhibit less intrinsic efficacy than UTP was examined by assessing their capacity at high concentrations to inhibit the effect of a near-maximal concentration of UTP (Fig. 5A) . No inhibitory effect on the action of UTP was observed with any of these phosphonate analogues.
Concentration effect curves for UTP also were carried out in the absence and presence of a high (100 M) concentration of 7c or 7f to determine whether the activity of these molecules was consistent with that of agonists acting at the orthosteric or an allosteric site of the P2Y 2 receptor. As illustrated in Fig. 5 , neither 7c nor 7f affected the potency of UTP. These results are consistent with the idea that the uridine 5'-phosphonate analogues act at an allosteric site rather than the orthosteric binding pocket to produce their effect on P2Y 2 receptor activity. 
Conformational Analysis
The furanose ring of nucleotides displays a characteristic equilibrium between two favored puckering conformations, i.e. the (N) and South (S) state. 29 Davies et al. 30 For compound 3, the (N) and (S) conformers are nearly equally present, with a small preference for the (N). From Table 1 , it appears that compound 7a has similar (N)/(S) populations as 3. It can therefore be concluded that the incorporation of a phenyl group at the C-5 position appears to have no effect on the conformational state of the ribofuranose ring.
Interestingly, this is in contrast to the effect of implanting a phenyl ring at C-6 of the base as was published recently by Nencka et al., 31 that clearly shows an enhanced preference for the (N) conformation. A second aspect of the conformation is the orientation of the base relative to the ring structure, which is here assumed to be either syn (with the substituent pointing away from the ring) or anti (with the substituent pointing towards the ring). The NOESY spectrum of 3 confirmed that the anti rotamer could be adopted. However, when a bulky group is implanted at the C-5 position, it orients away from the ribose ring, meaning that in this case only the syn rotamer will be available.
Conclusions
In this study we explored the influence of modifications of uridine 5'-methylenephosphonate (3) on activity at the human P2Y 2 receptor. A Suzuki-Miyaura coupling of a suitable 5-bromo precursor with aryl and heteroaryl boronic acids allowed generation of a small series of C-5 substituted analogues of 3. All 5-modified analogues caused P2Y 2 receptor-dependent inositol phosphate accumulation. Within this series, 5-(2-furanyl) (7f), 5-(4-fluorophenyl) (7c), and thien-2-yl (7g) substitutions afforded the highest potencies. Interestingly, none of the phosphonate analogues exhibited the same maximal activity as UTP, and these analogues failed to inhibit activity of UTP down to the level of activity observed with the 5-modified analogues alone as would be expected for classical partial agonists acting at the orthosteric binding pocket. Indeed, no change in the concentration effect curve to UTP occurred in the presence of supramaximal concentrations of 7c or 7f. These results are consistent with the concept that these analogues allosterically activate the P2Y 2 receptor in a manner that has no obvious influence on the effects of UTP mediated through its orthosteric binding site.
Although our observations strongly suggest allosteric regulation by the phosphonate analogues, they do not prove it, and the lack of availability of a radioligand for direct assessement of the orthosteric binding site prevents more confident conclusions about their mechanism of action. By altering the sugar part of 3, we showed that the SAR in the phosphonate series does not fully parallel that observed in the triphosphate class, further
suggesting that the current phosphonates may bind at a site that differs from the cognate agonist binding pocket.
Experimental Section Chemical Synthesis
All reagents were from standard commercial sources and of analytic grade. Precoated Merck silica gel F254 plates were used for TLC, spots were examined under ultraviolet light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was 
1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-2',3'-O-isopropylidene-β-D-ribohexofuranosyl]-5-bromouracil (5)
To a solution of compound 4 9 (399 mg, 0.95 mmol) in DMF (8 mL 
General procedure for the synthesis of 5-modified nucleoside phosphonates via SuzukiMiyaura coupling (6a-h)
A mixture of compound 5 (1 equiv.), aryl boronic acid (2 equiv.), Pd(PPh 3 ) 4 (0.1 equiv.) and Na 2 CO 3 (3.3 equiv.) in DMF and degassed H 2 O was heated (± 130 °C, oil bath) under argon for 6 h or until TLC indicated consumption of all starting material. The mixture was then concentrated and co-distilled with toluene. The residue was purified by column chromatography affording 5-modified analogues 6a-h in moderate yield. 
1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-2',3'-O-isopropylidene-β-D-ribohexofuranosyl]-5-phenyluracil (6a)

1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-2',3'-O-isopropylidene-β-D-ribohexofuranosyl]-5-(naphthalen-2-yl)uracil (6b)
Reaction of compound 5 (63 mg, 0.13 mmol) with naphthalene- 
1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-2',3'-O-isopropylidene-β-D-ribohexofuranosyl]-5-(thien-2-yl)uracil (6g)
1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-2',3'-O-isopropylidene-β-D-ribohexofuranosyl]-5-(benzothiophen-3-yl)uracil (6h)
Reaction of compound 5 (105 mg, 0.21 mmol) with 1-benzothiophen-3-ylboronic acid (77 mg, 0.42 mmol), Pd(PPh 3 ) 4 (24 mg, 0.021 mmol) and Na 2 CO 3 (74 mg, 0.70 mmol) in DMF (5 mL) and degassed H 2 O (0.7 mL) was performed as described in the general procedure for the synthesis of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-phenyluracil (7a)
Phosphonic ester 6a (32 mg, 0.068 mmol) was dissolved in 1.4 mL of CH 2 Cl 2 under argon and treated with TMSBr (18 μL, 1.35 mmol) and the solution was stirred overnight. The solvents were evaporated and the residue was co-distilled with toluene. Then, 0.7 mL of H 2 O was added followed by 1.4 mL of a 50% aqueous TFA solution and the mixture was stirred 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(naphthalen-2-yl)uracil (7b)
Reaction of compound 6b (70 mg, 0.073 mmol) with TMSBr (19 μL, 1.46 mmol), work-up and purification as described for 7a, afforded compound 7b as a white powder (22.6 mg, 39% 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(4-fluorophenyl)uracil (7c)
Reaction of compound 6c (56 mg, 0.11 mmol) with TMSBr (29 μL, 2.20 mmol), work-up and purification as described for 7a, afforded compound 7c as a white powder (26.1 mg, 57%). 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-styryluracil (7d)
Reaction of compound 6d (72 mg, 0.14 mmol) with TMSBr (36 μL, 2.75 mmol), work-up and purification as described for 7a, afforded compound 7d as a white powder (6.5 mg, 11% 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(p-tolyl)uracil (7e)
Reaction of compound 6e (29 mg, 0.058 mmol) with TMSBr (15 μL, 1.15 mmol) work-up and purification as described for 7a, afforded compound 7e as a white powder (4.3 mg, 18%). 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(furan-2-yl)uracil (7f)
Reaction of compound 6f (32 mg, 0.067 mmol) with TMSBr (18 μL, 1.34 mmol), work-up and purification as described for 7a, afforded compound 7f as a white powder (5.8 mg, 22%). 
1-[5',6'-Dideoxy-6'-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(thien-2-yl)uracil (7g)
Reaction of compound 6g (32 mg, 0.063 mmol) with TMSBr (17 μL, 1.26 mmol), work-up and purification as described for 7a, afforded compound 7g as a white powder (9.3 mg, 37%). 
1-[5',6'-Dideoxy-6'-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (8)
A solution of compound 4 (428 mg, 1.02 mmol) and 50% aq HCOOH (10 mL) was stirred for 4.5 h at room temperature. The mixture was evaporated in vacuo and purified on a silica column using CH 2 Cl 2 /MeOH (90:10) as a solvent. 
5'-[(Diethoxyphosphinyl)methoxy]-β-D-uridine (21)
Compound 20 (37 mg, 0.11 mmol) was dissolved in a 5:1 acetone-H 2 O mixture (4 mL) and 
Assay of PLC activity
Stable cell lines for study of the human P2Y 2, P2Y 4 , and P2Y 6 receptors were generated by retroviral expression of the receptor in 1321N1 human astrocytoma cells, which do not natively express P2Y receptors. Incubations were terminated by aspiration of the drug-containing medium and addition of 90 μL of ice-cold 50 mM formic acid. After 30 min, supernatants were neutralized with 30 μL of 150 mM NH 4 OH and applied to Dowex AG1-X8 anion exchange columns. Total inositol phosphates were eluted and radioactivity was measured using a liquid scintillation counter.
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Data Analysis
Agonist potencies (EC 50 values) were determined from concentration-response curves by nonlinear regression analysis using the GraphPad software package Prism (GraphPad, San Diego, CA). Each concentration of drug was tested in triplicate assays, and concentration effect curves for each test drug were repeated in at least three separate experiments with freshly diluted molecule. The results are presented as mean ± SEM from multiple experiments or in the case of concentration effect curves from a single experiment carried out with triplicate assays that were representative of results from multiple experiments.
Supplementary Material: NMR spectra and HPLC traces for selected derivatives are available.
